Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab

Abstract

Objective: Therapeutic drug monitoring is used clinically to guide anti-tumor necrosis factor (TNF) therapy for inflammatory bowel disease (IBD), but its use for ustekinumab (UST) remains unclear. This study aimed to determine predictive variables of UST levels.

Methods: In this retrospective cohort of patients with IBD, UST trough levels were drawn at maintenance dosing. Relationships between UST trough levels and demographics, therapy, and outcomes were analyzed. Machine-learning models were used to infer combinatorial traits predictive of UST levels.

Results: Altogether 177 patients with IBD on UST had a mean UST trough level of 4.742 μg/mL. The injection schedule correlated significantly (P < 0.001) with UST levels. Naiveté to anti-TNFs correlated with higher UST levels (P = 0.048). Univariate analysis revealed that higher inflammatory biomarkers significantly correlated to lower UST levels and a lower Simple Endoscopic Score to Crohn's Disease to adequate UST levels (P = 0.018). Multivariate analysis identified body mass index (BMI), previous anti-TNF failure, and laboratory flare as predictors of UST levels with an area under the receiver operating characteristic curve (AUROC) of 0.72. The UST cut-off level of 5.77 μg/mL yielded a 0.79 AUROC, 80% sensitivity, and 81% specificity for predicting endoscopic remission of Crohn's disease. For the clinical remission end-point in ulcerative colitis, UST level of 4.73 μg/mL yielded a 0.69 AUROC, 53% sensitivity, and 86% specificity.

Conclusions: Higher UST levels correlated with less disease activity. BMI was an important consideration for UST response as well. Therefore, UST dose adjustments to reach target levels may optimize response.

Keywords

biological products / drug monitoring / inflammatory bowel diseases / machine learning / ustekinumab

References

[1] Papamichael K, Afif W, Drobne D, et al; International Consortium for Therapeutic Drug Monitoring. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022;7(2):171-185.

[2] Alsoud D, Vermeire S, Verstockt B. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope? Curr Opin Pharmacol. 2020;55:17-30.

[3] Verstockt B, Dreesen E, Noman M, et al. Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates. J Crohns Colitis. 2019;13(7):864-872.

[4] Painchart C, Brabant S, Duveau N, et al. Ustekinumab serum trough levels may identify suboptimal responders to ustekinumab in Crohn's disease. Dig Dis Sci. 2020;65(5):1445-1452.

[5] Soufflet N, Boschetti G, Roblin X, et al. Concentrations of ustekinumab during induction therapy associate with remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2019;17(12):2610-2612.

[6] Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018;113(4):481-517.

[7] Verdon C, Vande Casteele N, Heron V, Germain P, Afif W. Comparison of serum concentrations of ustekinumab obtained by three commercial assays in patients with Crohn's disease. J Can Assoc Gastroenterol. 2021;4(2):73-77.

[8] Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease. Gastroenterology. 2018;154(6):1660-1671.

[9] Adedokun OJ, Xu Z, Marano C, et al. Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(10):2244-2255.e9.

[10] Liefferinckx C, Bottieau J, Toubeau JF, et al. Collecting new peak and intermediate infliximab levels to predict remission in inflammatory bowel diseases. Inflamm Bowel Dis. 2022;28(2):208-217.

[11] Friedman JH. Greedy function approximation: a gradient boosting machine. Ann Statist. 2001;29(5):1189-1232.

[12] Toubeau JF, Bottieau J, Vallée F, De Grève Z. Deep learning-based multivariate probabilistic forecasting for short-term scheduling in power markets. IEEE Trans Power Syst. 2019;34(2):1203-1215.

[13] Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.

[14] Zweegers J, van den Reek JMPA, van de Kerkhof PCM, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175(2):340-347.

[15] Del Alcázar E, Ferran M, López-Ferrer A, et al. Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. J Dermatolog Treat. 2020;31(3):222-226.

[16] McDonald C, Kerr H, Gibbons E, et al. Higher ustekinumab levels in maintenance therapy are associated with greater mucosal healing and mucosal response in Crohn's disease: an experience of 2 IBD centers. Inflamm Bowel Dis. 2024;30(3):423-428.

[17] Walshe M, Borowski K, Battat R, et al. Serum ustekinumab concentrations are associated with remission in Crohn's disease defined by a serum-based endoscopic healing index. Crohns Colitis 360. 2021;3(3):otab032.

RIGHTS & PERMISSIONS

2024 The Authors. Journal of Digestive Diseases published by Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.